ClinicalTrials.gg
CompletedNCT04908865Updated May 11, 2026Results posted

Open-label Study of Belimumab Plus Standard Therapy in Chinese Pediatric Participants With Active Systemic Lupus Erythematosus (SLE)

A Phase 4 interventional study of Belimumab and Standard therapy in Systemic Lupus Erythematosus, sponsored by GlaxoSmithKline. Completed at 9 sites in China. Open to participants aged 5 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-05-11.

Sponsored by GlaxoSmithKline · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
67
Allocation
Not applicable
Ages
5 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 36 studies testing belimumab in Lupus Erythematosus, Systemic — 4 open to participants now, 7 under way, none of them phase 3. belimumab · Lupus Erythematosus, Systemic.

Enrollment
26th of 36
67 · median 81
Started
2021
with 3 others
Phase 4
10 of 36
2 open now
Registered
29th of 36
by date
Lead sponsor
13 of 36
GlaxoSmithKline

Among the 36 studies testing belimumab in Lupus Erythematosus, Systemic, this one is the 26th largest by enrollment, is one of 4 that started in 2021, is one of 10 in phase 4, and was the 29th registered.

Lupus Erythematosus, Systemic

1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

4 of the 36 studies testing belimumab in Lupus Erythematosus, Systemic are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About belimumab

belimumab: first FDA approval 2011 (BENLYSTA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.

This study: 5 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing belimumab in Lupus Erythematosus, Systemic, or all of them as a file.
02

Study summary

This study will be conducted to evaluate the safety, efficacy and pharmacokinetics of belimumab administered in combination with background standard therapy in pediatric participants with active SLE.

03

Conditions studied

  • Systemic Lupus Erythematosus

Keywords

  • Pediatric
  • Belimumab
  • Pharmacokinetics
  • Active Systemic Lupus Erythematosus
  • Safety
  • Efficacy
04

Who can participate

Ages eligible
5 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants have or have had in series, 4 or more of the American College of Rheumatology (ACR) 11 criteria for the classification of SLE.
  • Participant's age is 5 to 17 years at the time of .
  • Have active SLE disease defined as a SELENA SLEDAI score >= 8 at screening (SELENA SLEDAI scoring).
  • Have unequivocally positive autoantibody test results defined as an anti-nuclear antibody (ANA) titer >=1:80 and/or a positive anti-Double stranded deoxyribonucleic acid (dsDNA) serum antibody test.
  • Are on a stable SLE therapy at Baseline. The stable treatment at Baseline consists of , anti-malarials, /immunomodulatory agents and Non-steroidal anti-inflammatory drugs (NSAIDs), alone or in combination, at a fixed dose for a period of at least 30 days prior to Day 0.
  • No gender restriction. use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
  • The investigator, or a person designated by the investigator, will obtain written informed assent from each study participant or the participant's legally acceptable representative, parent(s), or legal guardian and the participant's assent, when applicable, before any study-specific activity is performed. The investigator will retain the original copy of each participant's signed assent document.

Exclusion criteria

Exclusion Criteria:

  • Have an estimated (eGFR) as calculated by Schwartz Formula of less than 30 mL/minutes.
  • Have acute severe nephritis defined as a significant worsening of renal disease (for example [e.g.], the presence of urinary sediments and other lab abnormalities) that, in the opinion of the study investigator, may lead to the participant requiring induction therapy with intravenous (IV) cyclophosphamide, Mycophenolate mofetil (MMF) or high dose during the first 6 months of the study.
  • Have a history of a major organ transplant (e.g., heart, lung, kidney, liver) or hematopoietic stem cell/marrow transplant.
  • Have clinical evidence of significant, unstable or uncontrolled, acute or chronic diseases not due to SLE (cardiovascular, pulmonary, hematologic, gastrointestinal, hepatic, renal, neurological, or infectious diseases) which, in the opinion of the investigator, could confound the results of the study or put the participant at undue risk.
  • Have a planned surgical procedure or a history of any other medical disease (e.g., cardiopulmonary), laboratory abnormality, or condition (e.g., poor venous access) that, in the opinion of the investigator, makes the participant unsuitable for the study.
  • Have a history of malignant neoplasm within the last 5 years.
  • Have a history of a primary immunodeficiency.
  • Have an Immunoglobulin A (IgA) deficiency (IgA level less than [\<]10 mg/deciliters [milligrams/dL]).
  • Have acute or chronic infections requiring management.
  • Have recent infections that, in the opinions of the investigator, makes the participant unsuitable for the study or could put the participant at undue risk.
  • Have current drug or alcohol abuse or dependence, or a history of drug or alcohol abuse or dependence within 364 days prior to Day 0.
  • Have a Grade 3 or greater laboratory abnormality based on the protocol toxicity scale except for the following that are allowed:

    1. Stable Grade 3 (PT) secondary to warfarin treatment.
    2. Stable Grade 3 partial thromboplastin time (PTT) due to lupus anticoagulant and not related to liver disease or anti-coagulant therapy.
    3. Stable Grade 3 hypoalbuminemia due to lupus nephritis and not related to liver disease or malnutrition.
    4. Any grade proteinuria
    5. Stable Grade 3 gamma glutamyl transferase (GGT) elevation due to lupus hepatitis and not related to alcoholic liver disease, uncontrolled diabetes or viral hepatitis. If present, any abnormalities in the (ALT) and/or Aspartate aminotransferase (AST) must be Grade 2.
    6. Stable Grade 3 neutropenia; or stable Grade 3 lymphopenia; or stable Grade 3 leukopenia, due to SLE
  • Have a history of an anaphylactic reaction to parenteral administration of contrast agents, human or murine proteins or monoclonal antibodies.
  • Have evidence of serious suicide risk including any history of suicidal behavior in the last 6 months or who in the investigator's judgment, poses a significant suicide risk.
  • Have received treatment with belimumab at any time.
  • Have received any of the following within 364 days of Day 0:

    1. Treatment with any B-cell targeted
    2. Abatacept
    3. A biologic agent
  • Have required 3 or more courses of systemic corticosteroids for concomitant conditions (e.g., asthma, atopic dermatitis) within 90 days of Day 0.
  • Have received any of the following within 90 days of Day 0:

    1. Anti-Tumour Necrosis Factor (TNF) or anti-interleukin (IL)-6 therapy (e.g., adalimumab, etanercept, infliximab, tocilizumab certolizumab, golimumab)
    2. Interleukin-1 receptor antagonist (anakinra)
    3. Intravenous immunoglobulin (IVIG)
    4. Plasmapheresis
  • Have received any of the following within 30 days of Day 0:

    1. IV cyclophosphamide
    2. A non-biologic investigational agent (30 days window OR 5 half-lives, whichever is longer)
    3. Any new /immunomodulatory agent, anti-malarial, NSAID
    4. High dose prednisone or equivalent (>1.5 mg/kilogram/day) or any intramuscular or intravenous steroid injection.
  • Have received a live or within 30 days of Day 0.
  • Have active central nervous system (CNS) lupus (including seizures, psychosis, organic brain syndrome, cerebrovascular accident [CVA], cerebritis or CNS vasculitis) requiring therapeutic intervention within 60 days of Day 0.
  • Have required renal replacement therapy (e.g., hemodialysis, peritoneal dialysis) within 90 days of Day 0 or be currently on renal replacement therapy.
  • Participation in an interventional clinical study either concurrently or within 6 months of screening. Participation in an observational study may be permitted.
  • Have a historically positive test or test positive at screening for (HIV) antibody.
  • Evidence of active or latent tuberculosis (TB) as documented by medical history and examination, chest X-rays (posteroanterior) and a positive (not indeterminate) QuantiFERON-TB Gold Plus test.
  • : Serologic evidence of Hepatitis B (HB) infection defined as Hepatitis B surface antigen positive (HBsAg+) or Hepatitis B core antibody positive (HBcAb+).
  • : Positive test for Hepatitis C antibody at screening.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
67 participants (actual)

Study arms

  • Experimental
    Pediatric participants receiving belimumab

    Drug: Belimumab · Drug: Standard therapy

Interventions

  • Belimumab will be administered.

  • DrugStandard therapy

    Standard therapy will be continued.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events of Special Interest (AESIs) Through Week 52

    An adverse event (AE) is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. AESIs included malignancies, post-infusion systemic or hypersensitivity reactions, infections (including serious infections of special interest), and depression, suicide, or self-injury. Infections of special interest included opportunistic infections (OI), herpes zoster (HZ), tuberculosis (TB), and sepsis. Number of participants with AESIs as identified by custom Medical Dictionary for Regulatory Activities (MedDRA) query has been reported.

    Time frame: Up to Week 52

  2. Number of Participants With Greater Than Equal to (>=) 4 Points Reduction From Baseline to Week 52 in Safety of Estrogen in Lupus National Assessment - Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI) Score

    The SELENA-SLEDAI score is a cumulative and weighted index for assessing SLE disease activity in participants with SLE. It consists of 24 disease descriptors related to signs and symptoms, laboratory tests, and physician's assessment across 9 organ systems. Each descriptor is assigned a weighted score (8 descriptors with a weight of 8 each, 6 descriptors with a weight of 4 each, 7 descriptors with a weight of 2 each, and 3 descriptors with a weight of 1 each) which is added up if the descriptor is observed during a visit or within the preceding 10 days. The total score ranges from 0 (no disease activity) to 105 (all 24 descriptors present simultaneously). A higher score indicates a more significant degree of disease activity. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Number of participants with a decrease of 4 points or more in the score at Week 52 compared to their Baseline score is presented.

    Time frame: Baseline (Day 0) and Week 52

Secondary outcomes

  1. Number of Participants With AEs and Serious Adverse Events (SAEs) Through Week 52

    An AE is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An SAE is defined as any untoward medical occurrence that, at any dose: results in death, is life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability or incapacity, is a birth defect or congenital anomaly, or other situations as per the medical or scientific judgment of the investigator. Number of participants with AEs and SAEs has been reported.

    Time frame: Up to Week 52

  2. Percentage of Participants With >=4 Points Reduction From Baseline in SELENA-SLEDAI Score by Each Visit

    The SELENA-SLEDAI score is a cumulative and weighted index for assessing SLE disease activity in participants with SLE. It consists of 24 disease descriptors related to signs and symptoms, laboratory tests, and physician's assessment across 9 organ systems. Each descriptor is assigned a weighted score (8 descriptors with a weight of 8 each, 6 descriptors with a weight of 4 each, 7 descriptors with a weight of 2 each, and 3 descriptors with a weight of 1 each) which is added up if the descriptor is observed during a visit or within the preceding 10 days. The total score ranges from 0 (no disease activity) to 105 (all 24 descriptors present simultaneously). A higher score indicates a more significant degree of disease activity. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Percentage of participants with a decrease of 4 points or more in the score at each visit compared to their Baseline score is presented.

    Time frame: Baseline (Day 0) and Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52

  3. Change From Baseline to Week 52 in Physician Global Assessment (PGA)

    The PGA is used to assess the participant's current disease activity by investigator. It is collected on a 10 centimeter (cm) visual analogue scale. The score ranges from 0 (no activity) to 3 (severe activity). Lower score means no disease activity, higher score means severe disease activity. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.

    Time frame: Baseline (Day 0) and Week 52

  4. Change From Baseline to Week 52 in Parent Global Assessment (ParentGA)

    The ParentGA is used to assess the participant's overall well-being at the moment rated on a 21-numbered circle visual analog scale by the parent. The score ranges from 0 (very well) to 10 (very poorly). Higher score indicates worse effect of the illness on the child. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.

    Time frame: Baseline (Day 0) and Week 52

  5. Change From Baseline in Average Daily Prednisone Equivalent Dose at Week 52

    The average daily prednisone equivalent dose accounted for all steroids taken IV, intramuscularly (IM), subcutaneously (SC), intradermally, and orally for both SLE and non-SLE reasons. All steroid dosages were converted to a prednisone equivalent in mg at each visit. The daily prednisone equivalent dose for a steroid was calculated as follows: collected dose of the steroid in mg multiplied by (\*) conversion factor \* frequency factor. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. At Baseline, the average daily prednisone equivalent dose was the sum of all prednisone doses over 7 consecutive days up to but not including Day 0, divided by 7. The average daily prednisone dose at Week 52 visit was the sum of all prednisone doses over 7 consecutive days up to and including the Week 52 visit, divided by 7. Average daily prednisone equivalent dose was expressed in milligrams per day.

    Time frame: Baseline (Day 0) and Week 52

  6. Time to First Flare Over 52 Weeks

    The SLE flare index (SFI) is used to categorize SLE flares as mild/moderate or severe. A mild/moderate SFI flare involves: a SELENA-SLEDAI score increase of 3 to 12 points (higher score means greater disease activity); SLE symptom development; prednisone dose increase (but not above 0.5 milligrams per kilogram per day \[mg/kg/day\]); non-steroidal anti-inflammatory drugs (NSAIDs)/hydroxychloroquine addition; or PGA score increase by 1 or more, but not to more than 2.5 (higher score means greater disease activity). A severe SFI flare involves: SELENA-SLEDAI score increase over 12 points; onset or worsening of severe SLE symptoms; prednisone dose increase above 0.5 mg/kg/day; introduction of potent immunosuppressants; hospitalization; or PGA score reaching 2.5 or higher. Time to first SLE flare (mild/moderate or severe) was the number of days from treatment start date until the participant met an event. Time to first flare was defined as event date minus treatment start date plus 1.

    Time frame: Up to Week 52

  7. Time to First Severe Flare Over 52 Weeks

    The SFI is used to categorize SLE flares as mild/moderate or severe. A severe SFI flare involves SELENA-SLEDAI score increase over 12 points (higher score means greater disease activity), onset or worsening of severe SLE symptoms, prednisone dose increase above 0.5 mg/kg/day, introduction of potent immunosuppressants, hospitalization, or PGA score reaching 2.5 or higher (higher score means higher disease activity). Time to first severe SLE flare was the number of days from treatment start date until the participant met an event. Time to first severe flare was defined as event date minus treatment start date plus 1.

    Time frame: Up to Week 52

  8. Median Belimumab Concentration Levels at Day 0, 7, and 14 Days Post First Dose, and Pre-infusion and Post-infusion at Day 84

    Blood samples were collected at indicated time points for measurement of plasma concentrations of belimumab.

    Time frame: Days 0, 7, and 14 days post first dose, and pre-infusion and post-infusion at Day 84

  9. Apparent Total Clearance of Belimumab

    Blood samples were collected at indicated time points for PK analysis of belimumab.

    Time frame: Days 0, 7, and 14 days post first dose, and pre-infusion and post-infusion at Day 84

  10. Volume of Distribution of Belimumab

    Blood samples were collected at indicated time points for PK analysis of belimumab.

    Time frame: Days 0, 7, and 14 days post first dose, and pre-infusion and post-infusion at Day 84

  11. Terminal Half-life (t1/2) of Belimumab

    Blood samples were collected at indicated time points for PK analysis of belimumab.

    Time frame: Days 0, 7, and 14 days post first dose, and pre-infusion and post-infusion at Day 84

  12. Maximum Plasma Concentration (Cmax) of Belimumab at Steady State

    Blood samples were collected at indicated time points for PK analysis of belimumab.

    Time frame: Days 0, 7, and 14 days post first dose, and pre-infusion and post-infusion at Day 84

  13. Minimum Plasma Concentration Reached Prior to Administration of Next Dose (Cmin) of Belimumab at Steady State

    Blood samples were collected at indicated time points for PK analysis of belimumab.

    Time frame: Days 0, 7, and 14 days post first dose, and pre-infusion and post-infusion at Day 84

  14. Average Plasma Concentration (Cavg) of Belimumab at Steady State

    Blood samples were collected at indicated time points for PK analysis of belimumab.

    Time frame: Days 0, 7, and 14 days post first dose, and pre-infusion and post-infusion at Day 84

  15. Area Under the Concentration Curve (AUC) of Belimumab at Steady State

    Blood samples were collected at indicated time points for PK analysis of belimumab.

    Time frame: Days 0, 7, and 14 days post first dose, and pre-infusion and post-infusion at Day 84

07

Results

Posted Jul 23, 2025

Participant flow

Participant flow — Overall Study
MilestoneBelimumab
Started67
Pharmacokinetic (pk) population26
Completed59
Not completed8
Withdrew: Adverse event2
Withdrew: Lack of efficacy5
Withdrew: Lost to follow-up1

Outcome measures

PrimaryNumber of Participants With Adverse Events of Special Interest (AESIs) Through Week 52

An adverse event (AE) is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. AESIs included malignancies, post-infusion systemic or hypersensitivity reactions, infections (including serious infections of special interest), and depression, suicide, or self-injury. Infections of special interest included opportunistic infections (OI), herpes zoster (HZ), tuberculosis (TB), and sepsis. Number of participants with AESIs as identified by custom Medical Dictionary for Regulatory Activities (MedDRA) query has been reported.

Time frame:
Up to Week 52
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events of Special Interest (AESIs) Through Week 52
ParticipantsBelimumab
All malignancies0
Post-infusion systemic reactions (PISR)0
All infections of special interest (OI, HZ, TB, sepsis)2
Depression (including mood disorders and anxiety)/suicide/self-injury0
PrimaryNumber of Participants With Greater Than Equal to (>=) 4 Points Reduction From Baseline to Week 52 in Safety of Estrogen in Lupus National Assessment - Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI) Score

The SELENA-SLEDAI score is a cumulative and weighted index for assessing SLE disease activity in participants with SLE. It consists of 24 disease descriptors related to signs and symptoms, laboratory tests, and physician's assessment across 9 organ systems. Each descriptor is assigned a weighted score (8 descriptors with a weight of 8 each, 6 descriptors with a weight of 4 each, 7 descriptors with a weight of 2 each, and 3 descriptors with a weight of 1 each) which is added up if the descriptor is observed during a visit or within the preceding 10 days. The total score ranges from 0 (no disease activity) to 105 (all 24 descriptors present simultaneously). A higher score indicates a more significant degree of disease activity. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Number of participants with a decrease of 4 points or more in the score at Week 52 compared to their Baseline score is presented.

Time frame:
Baseline (Day 0) and Week 52
Reported as:
Count of participants · Participants
Number of Participants With Greater Than Equal to (>=) 4 Points Reduction From Baseline to Week 52 in Safety of Estrogen in Lupus National Assessment - Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI) Score
ParticipantsBelimumab
Number of Participants With Greater Than Equal to (>=) 4 Points Reduction From Baseline to Week 52 in Safety of Estrogen in Lupus National Assessment - Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI) Score44
SecondaryNumber of Participants With AEs and Serious Adverse Events (SAEs) Through Week 52

An AE is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An SAE is defined as any untoward medical occurrence that, at any dose: results in death, is life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability or incapacity, is a birth defect or congenital anomaly, or other situations as per the medical or scientific judgment of the investigator. Number of participants with AEs and SAEs has been reported.

Time frame:
Up to Week 52
Reported as:
Count of participants · Participants
Number of Participants With AEs and Serious Adverse Events (SAEs) Through Week 52
ParticipantsBelimumab
AEs56
SAEs19
SecondaryPercentage of Participants With >=4 Points Reduction From Baseline in SELENA-SLEDAI Score by Each Visit

The SELENA-SLEDAI score is a cumulative and weighted index for assessing SLE disease activity in participants with SLE. It consists of 24 disease descriptors related to signs and symptoms, laboratory tests, and physician's assessment across 9 organ systems. Each descriptor is assigned a weighted score (8 descriptors with a weight of 8 each, 6 descriptors with a weight of 4 each, 7 descriptors with a weight of 2 each, and 3 descriptors with a weight of 1 each) which is added up if the descriptor is observed during a visit or within the preceding 10 days. The total score ranges from 0 (no disease activity) to 105 (all 24 descriptors present simultaneously). A higher score indicates a more significant degree of disease activity. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Percentage of participants with a decrease of 4 points or more in the score at each visit compared to their Baseline score is presented.

Time frame:
Baseline (Day 0) and Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
Reported as:
Number · Percentage of Participants
Percentage of Participants With >=4 Points Reduction From Baseline in SELENA-SLEDAI Score by Each Visit
Percentage of ParticipantsBelimumab
Week 439.8
Week 851.8
Week 1268.9
Week 1669.0
Week 2065.4
Week 2468.1
Week 2865.7
Week 3267.7
Week 3669.1
Week 4075.1
Week 4474.2
Week 4871.3
Week 5266.7
SecondaryChange From Baseline to Week 52 in Physician Global Assessment (PGA)

The PGA is used to assess the participant's current disease activity by investigator. It is collected on a 10 centimeter (cm) visual analogue scale. The score ranges from 0 (no activity) to 3 (severe activity). Lower score means no disease activity, higher score means severe disease activity. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.

Time frame:
Baseline (Day 0) and Week 52
Reported as:
Mean · Scores on scale
Change From Baseline to Week 52 in Physician Global Assessment (PGA)
Scores on scaleBelimumab
Change From Baseline to Week 52 in Physician Global Assessment (PGA)-0.931 ± 0.6046
SecondaryChange From Baseline to Week 52 in Parent Global Assessment (ParentGA)

The ParentGA is used to assess the participant's overall well-being at the moment rated on a 21-numbered circle visual analog scale by the parent. The score ranges from 0 (very well) to 10 (very poorly). Higher score indicates worse effect of the illness on the child. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.

Time frame:
Baseline (Day 0) and Week 52
Reported as:
Mean · Scores on scale
Change From Baseline to Week 52 in Parent Global Assessment (ParentGA)
Scores on scaleBelimumab
Change From Baseline to Week 52 in Parent Global Assessment (ParentGA)-2.71 ± 2.713
SecondaryChange From Baseline in Average Daily Prednisone Equivalent Dose at Week 52

The average daily prednisone equivalent dose accounted for all steroids taken IV, intramuscularly (IM), subcutaneously (SC), intradermally, and orally for both SLE and non-SLE reasons. All steroid dosages were converted to a prednisone equivalent in mg at each visit. The daily prednisone equivalent dose for a steroid was calculated as follows: collected dose of the steroid in mg multiplied by (\*) conversion factor \* frequency factor. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. At Baseline, the average daily prednisone equivalent dose was the sum of all prednisone doses over 7 consecutive days up to but not including Day 0, divided by 7. The average daily prednisone dose at Week 52 visit was the sum of all prednisone doses over 7 consecutive days up to and including the Week 52 visit, divided by 7. Average daily prednisone equivalent dose was expressed in milligrams per day.

Time frame:
Baseline (Day 0) and Week 52
Reported as:
Mean · milligrams per day
Change From Baseline in Average Daily Prednisone Equivalent Dose at Week 52
milligrams per dayBelimumab
Change From Baseline in Average Daily Prednisone Equivalent Dose at Week 52-6.020 ± 9.2970
SecondaryTime to First Flare Over 52 Weeks

The SLE flare index (SFI) is used to categorize SLE flares as mild/moderate or severe. A mild/moderate SFI flare involves: a SELENA-SLEDAI score increase of 3 to 12 points (higher score means greater disease activity); SLE symptom development; prednisone dose increase (but not above 0.5 milligrams per kilogram per day \[mg/kg/day\]); non-steroidal anti-inflammatory drugs (NSAIDs)/hydroxychloroquine addition; or PGA score increase by 1 or more, but not to more than 2.5 (higher score means greater disease activity). A severe SFI flare involves: SELENA-SLEDAI score increase over 12 points; onset or worsening of severe SLE symptoms; prednisone dose increase above 0.5 mg/kg/day; introduction of potent immunosuppressants; hospitalization; or PGA score reaching 2.5 or higher. Time to first SLE flare (mild/moderate or severe) was the number of days from treatment start date until the participant met an event. Time to first flare was defined as event date minus treatment start date plus 1.

Time frame:
Up to Week 52
Reported as:
Median · days
Time to First Flare Over 52 Weeks
daysBelimumab
Time to First Flare Over 52 Weeks141.0 (58.0 to 333.0)
SecondaryTime to First Severe Flare Over 52 Weeks

The SFI is used to categorize SLE flares as mild/moderate or severe. A severe SFI flare involves SELENA-SLEDAI score increase over 12 points (higher score means greater disease activity), onset or worsening of severe SLE symptoms, prednisone dose increase above 0.5 mg/kg/day, introduction of potent immunosuppressants, hospitalization, or PGA score reaching 2.5 or higher (higher score means higher disease activity). Time to first severe SLE flare was the number of days from treatment start date until the participant met an event. Time to first severe flare was defined as event date minus treatment start date plus 1.

Time frame:
Up to Week 52
Reported as:
Median · days
Time to First Severe Flare Over 52 Weeks
daysBelimumab
Time to First Severe Flare Over 52 WeeksNA (289.0 to NA)
SecondaryMedian Belimumab Concentration Levels at Day 0, 7, and 14 Days Post First Dose, and Pre-infusion and Post-infusion at Day 84

Blood samples were collected at indicated time points for measurement of plasma concentrations of belimumab.

Time frame:
Days 0, 7, and 14 days post first dose, and pre-infusion and post-infusion at Day 84
Reported as:
Median · Micrograms per milliliter
Median Belimumab Concentration Levels at Day 0, 7, and 14 Days Post First Dose, and Pre-infusion and Post-infusion at Day 84
Micrograms per milliliterBelimumab
Day 0197.12 (141.93 to 257.37)
Day 771.36 (35.95 to 100.59)
Day 1437.86 (14.59 to 74.17)
Day 84, pre-infusion28.24 (2.35 to 89.07)
Day 84, post-infusion238.57 (139.19 to 357.03)
SecondaryApparent Total Clearance of Belimumab

Blood samples were collected at indicated time points for PK analysis of belimumab.

Time frame:
Days 0, 7, and 14 days post first dose, and pre-infusion and post-infusion at Day 84
Reported as:
Geometric mean · Milliliters per day
Apparent Total Clearance of Belimumab
Milliliters per dayBelimumab
Apparent Total Clearance of Belimumab155.39 ± 32.07
SecondaryVolume of Distribution of Belimumab

Blood samples were collected at indicated time points for PK analysis of belimumab.

Time frame:
Days 0, 7, and 14 days post first dose, and pre-infusion and post-infusion at Day 84
Reported as:
Geometric mean · Milliliters
Volume of Distribution of Belimumab
MillilitersBelimumab
Volume of Distribution of Belimumab3670.31 ± 23.66
SecondaryTerminal Half-life (t1/2) of Belimumab

Blood samples were collected at indicated time points for PK analysis of belimumab.

Time frame:
Days 0, 7, and 14 days post first dose, and pre-infusion and post-infusion at Day 84
Reported as:
Geometric mean · Days
Terminal Half-life (t1/2) of Belimumab
DaysBelimumab
Terminal Half-life (t1/2) of Belimumab17.43 ± 30.51
SecondaryMaximum Plasma Concentration (Cmax) of Belimumab at Steady State

Blood samples were collected at indicated time points for PK analysis of belimumab.

Time frame:
Days 0, 7, and 14 days post first dose, and pre-infusion and post-infusion at Day 84
Reported as:
Geometric mean · Micrograms per milliliter
Maximum Plasma Concentration (Cmax) of Belimumab at Steady State
Micrograms per milliliterBelimumab
Maximum Plasma Concentration (Cmax) of Belimumab at Steady State219.87 ± 18.13
SecondaryMinimum Plasma Concentration Reached Prior to Administration of Next Dose (Cmin) of Belimumab at Steady State

Blood samples were collected at indicated time points for PK analysis of belimumab.

Time frame:
Days 0, 7, and 14 days post first dose, and pre-infusion and post-infusion at Day 84
Reported as:
Geometric mean · Micrograms per milliliter
Minimum Plasma Concentration Reached Prior to Administration of Next Dose (Cmin) of Belimumab at Steady State
Micrograms per milliliterBelimumab
Minimum Plasma Concentration Reached Prior to Administration of Next Dose (Cmin) of Belimumab at Steady State36.92 ± 62.14
SecondaryAverage Plasma Concentration (Cavg) of Belimumab at Steady State

Blood samples were collected at indicated time points for PK analysis of belimumab.

Time frame:
Days 0, 7, and 14 days post first dose, and pre-infusion and post-infusion at Day 84
Reported as:
Geometric mean · Micrograms per milliliter
Average Plasma Concentration (Cavg) of Belimumab at Steady State
Micrograms per milliliterBelimumab
Average Plasma Concentration (Cavg) of Belimumab at Steady State75.09 ± 34.37
SecondaryArea Under the Concentration Curve (AUC) of Belimumab at Steady State

Blood samples were collected at indicated time points for PK analysis of belimumab.

Time frame:
Days 0, 7, and 14 days post first dose, and pre-infusion and post-infusion at Day 84
Reported as:
Geometric mean · Days*micrograms per milliliter
Area Under the Concentration Curve (AUC) of Belimumab at Steady State
Days*micrograms per milliliterBelimumab
Area Under the Concentration Curve (AUC) of Belimumab at Steady State2102.65 ± 34.37

Adverse events

Collected over All-cause mortality, SAEs, and non-serious adverse events (non-SAEs) were collected from the start of the study intervention (Day 0) up to the post-treatment follow-up visit at Week 64. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Belimumab0/67 (0%)20/67 (29.9%)57/67 (85.1%)
Most frequent serious events
Showing 10 of 23
Most frequent serious events
EventBelimumab
RashSkin and subcutaneous tissue disorders4/67
BronchitisInfections and infestations3/67
Systemic lupus erythematosusMusculoskeletal and connective tissue disorders3/67
HeadacheNervous system disorders2/67
PyrexiaGeneral disorders2/67
Interstitial lung diseaseRespiratory, thoracic and mediastinal disorders2/67
COVID-19Infections and infestations1/67
GastroenteritisInfections and infestations1/67
H1N1 influenzaInfections and infestations1/67
PneumoniaInfections and infestations1/67
Most frequent other events
Showing 10 of 124
Most frequent other events
EventBelimumab
Upper respiratory tract infectionInfections and infestations31/67
Coronavirus pneumoniaInfections and infestations11/67
COVID-19Infections and infestations9/67
CoughRespiratory, thoracic and mediastinal disorders9/67
Hepatic function abnormalHepatobiliary disorders9/67
PyrexiaGeneral disorders7/67
Lymphocyte count decreasedInvestigations5/67
BronchitisInfections and infestations4/67
White blood cell count decreasedInvestigations4/67
RashSkin and subcutaneous tissue disorders4/67

Baseline characteristics

Age, Continuous
Age, Continuous(YEARS)Belimumab
Mean13.0 ± 2.22
Sex: Female, Male
Sex: Female, Male(Participants)Belimumab
Female51
Male16
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Belimumab
Asian67
08

Study locations

9 sites
  • GSK Investigational Site
    Beijing, 100045, China
  • GSK Investigational Site
    Changchun, 130021, China
  • GSK Investigational Site
    Changsha, 410007, China
  • GSK Investigational Site
    Chongqing, 400014, China
  • GSK Investigational Site
    Hangzhou, 310052, China
  • GSK Investigational Site
    Nanjing, 210011, China
  • GSK Investigational Site
    Shanghai, 361006, China
  • GSK Investigational Site
    Suzhou, 215007, China
  • GSK Investigational Site
    Xi'an, 710054, China
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, a key secondary endpoints and safety data of the study.

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

Data sharing details ↗ · clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2021 to primary completion in May 2024, 31 months.

Results were first posted in Jul 2025, 1 year 2 months after primary completion.

Of 33 phase 4 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 42. This study's 31 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
May 26, 2021
First posted
Jun 1, 2021
StartActual
Oct 21, 2021
Primary completionActual
May 23, 2024
CompletionActual
Aug 13, 2024
Results first posted
Jul 23, 2025
Last update
May 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04908865
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jun 1, 2021
Start date
Oct 21, 2021
Primary completion
May 23, 2024
Completion
Aug 13, 2024
Results posted
Jul 23, 2025
Last update
May 11, 2026

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Belimumab

Start the discussion